Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + pomalidomide
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of ruxolitinib (a JAK1 and JAK2 inhibitor) and pomalidomide (an immunomodulating drug). Ruxolitinib works by inhibiting Janus kinase signaling pathways, which are involved in the pathophysiology of myelofibrosis. Pomalidomide inhibits angiogenesis and has direct anti-tumor effects. This combination has been studied primarily for the treatment of myelofibrosis.
- Brand names
- Jakafi + PomalystJakavi + Imnovid
- Other names
- ruxolitinib/pomalidomide
02
Targets
Beyond the preview
Go deeper on ruxolitinib + pomalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + pomalidomide.